Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.
Robert F SpieraLaura HummersLorinda ChungTracy M FrechRobyn DomsicVivien HsuDaniel E FurstJessica K GordonMaureen MayesRobert SimmsRobert LafyatisViktor MartyanovTammara WoodMichael L WhitfieldScott ConstantineElizabeth LeeNancy DgetluckBarbara WhitePublished in: Arthritis & rheumatology (Hoboken, N.J.) (2020)
Despite a short trial duration in a small number of patients in this phase II study in dcSSc, our findings indicate that lenabasum improves efficacy outcomes and underlying disease pathology with a favorable safety profile.
Keyphrases
- phase ii
- open label
- phase ii study
- systemic sclerosis
- double blind
- placebo controlled
- phase iii
- clinical trial
- interstitial lung disease
- study protocol
- end stage renal disease
- ejection fraction
- newly diagnosed
- rheumatoid arthritis
- locally advanced
- radiation therapy
- patient reported outcomes
- skeletal muscle
- rectal cancer
- insulin resistance